[Federal Register Volume 66, Number 156 (Monday, August 13, 2001)]
[Notices]
[Page 42549]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-20193]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting Susan S. 
Rucker, J.D., at the Office of Technology Transfer, National Institutes 
of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 
20852-3804; telephone: 301/496-7056 ext. 245; fax: 301/402-0220; e-
mail: [email protected]. A signed Confidential Disclosure Agreement 
will be required to receive copies of the patent applications.

Modified Leptin

YP Loh, NX Cawley (both of NICHD)
Serial No. 60/290,722 filed 14 May 2001

    This invention described and claimed in this patent application 
provides for an improved method for producing human leptin in vitro or 
in in vivo. In particular, the patent application describes 
compositions and methods which are based on a modified form of human 
leptin where the regulated secretory pathway (RSP) sorting signal has 
been modified to provide for the constitutive secretion of leptin via 
the nonregulated secretory pathway (NRSP) in a mammalian cell. This 
invention can be applied to a non-invasive method of gene therapy to 
achieve sustained delivery of this therapeutic protein.

Modified Growth Hormone

YP Loh, NX Cawley (both of NICHD), BJ Baum (NIDCR), and CR Snell
Serial No. 60/290,836 filed 14 May 2001

    This invention described and claimed in this patent application 
provides for an improved method for producing human growth hormone in 
vitro or in in vivo. In particular, the patent application describes 
compositions and methods which are based on a modified form of human 
growth hormone where the regulated secretory pathway (RSP) sorting 
signal has been modified to provide for the constitutive secretion of 
human growth hormone via the nonregulated secretory pathway (NRSP) in a 
mammalian cell. This invention can be applied to a non-invasive method 
of gene therapy to achieve sustained delivery of this therapeutic 
protein.

    Dated: August 6, 2001.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of 
Technology Transfer, National Institues of Health.
[FR Doc. 01-20193 Filed 8-10-01; 8:45 am]
BILLING CODE 4140-01-P